MYRIAD GENETICS INC
For the period ended Dec 31, 2023. Filed Feb 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 28, 2024
MYGN$5.67-1.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits and Financial Statement Schedules
(a)The following documents are included as part of this Annual Report on Form 10-K.
- Financial Statements
See “Index to Consolidated Financial Statements” under Part II, Item 8 to this Annual Report on Form 10-K.
- Financial Statement Schedules
Financial statement schedules have not been included because they are not applicable, or the information is included in financial statements or notes thereto.
- Exhibits
| ExhibitNumber · Exhibit Description · Filed with thisReport · Incorporated byReference hereinfrom Form orSchedule · Filing Date · SEC File/RegistrationNumber | ||||||
|---|---|---|---|---|---|---|
| 3.1 | Restated Certificate of Incorporation, as amended | 10-Q(Exhibit 3.1) | 8/4/2023 | 000-26642 | ||
| 3.2 | Restated By-Laws | 8-K (Exhibit 3.1) | 10/15/2020 | 000-26642 | ||
| 4.1 | Specimen Common Stock Certificate | 10-K(Exhibit 4.1) | 8/15/2011 | 000-26642 | ||
| 4.2 | Description of Securities | 10-KT (Exhibit 4.2) | 3/16/2021 | 000-26642 | ||
| Lease Agreements | ||||||
| 10.1 | .1 | Lease Agreement, dated October 12, 1995, between the Registrant and Boyer Research Park Associates V, by its general partner, the Boyer Company | 10-Q(Exhibit 10.2) | 11/8/1996 | 000-26642 | |
| .2 | Amendment to Phase I Lease Agreement, dated February 3, 2016, between the Registrant and HCPI/UTAH II, LLC. | 10-Q(Exhibit 10.1) | 5/4/2016 | 000-26642 | ||
| .3 | Lease Termination Agreement, dated December 18, 2023, between the Registrant and HCPI/Utah II, LLC | X | ||||
| 10.2 | .1 | Lease Agreement-Research Park Building Phase II, dated March 6, 1998, between the Registrant and Research Park Associated VI, by its general partner, the Boyer Company, L.C. | 10-K(Exhibit 10.44) | 9/24/1998 | 000-26642 | |
| .2 | Amendment to Phase II Lease Agreement, dated February 3, 2016, between Myriad Genetics, Inc. and HCPI/UTAH II, LLC. | 10-Q(Exhibit 10.2) | 5/4/2016 | 000-26642 | ||
| .3 | Lease Termination Agreement, dated December 18, 2023, between Myriad Genetics, Inc. and HCPI/Utah II, LLC. | X | ||||
| 10.3 | .1 | Lease Agreement, dated March 31, 2001, between the Registrant and Boyer Research Park Associates VI, by its general partner, The Boyer Company, L.C. | 10-Q(Exhibit 10.1) | 5/15/2001 | 000-26642 | |
| .2 | Amendment to Phase III Lease Agreement, dated February 3, 2016, between Myriad Genetics, Inc. and HCPI/UTAH II, LLC. | 10-Q(Exhibit 10.3) | 5/4/2016 | 000-26642 | ||
| ExhibitNumber · Exhibit Description · Filed with thisReport · Incorporated byReference hereinfrom Form orSchedule · Filing Date · SEC File/RegistrationNumber | ||||||
|---|---|---|---|---|---|---|
| .3 | Lease Termination Agreement, dated December 18, 2023, between Myriad Genetics, Inc. and HCPI/Utah II, LLC | X | ||||
| 10.4 | Lease Agreement, dated February 9, 2022, between Myriad Genetics, Inc. and Bay Bridge/Corporate, LLC. | X | ||||
| 10.5 | Lease, effective December 7, 2021, between Myriad Women's Health, Inc. and Bayside Area Development, LLC. | X | ||||
| Agreements with Executive Officers and Directors | ||||||
| 10.6 | Non-Employee Director Compensation Policy (effective June 2023)+ | 10-Q(Exhibit10.4) | 8/4/2023 | 000-26642 | ||
| 10.7 | Form of director and executive officer indemnification agreement+ | 10-K(Exhibit 10.34) | 8/25/2009 | 000-26642 | ||
| 10.8 | Form of Severance and Change in Control Agreement+ | 8-K (Exhibit 10.1) | 10/15/2020 | 000-26642 | ||
| 10.9 | Executive Employment Agreement between the Registrant and Paul J. Diaz dated July 24, 2020+ | 10-Q(Exhibit10.1) | 11/9/2020 | 000-26642 | ||
| 10.10 | Performance-Based Restricted Stock Unit Agreement between Registrant and Paul J. Diaz dated October 8, 2020+ | 10-Q(Exhibit10.2) | 11/9/2020 | 000-26642 | ||
| 10.11 | Restricted Stock Unit Agreement between the Registrant and Paul J. Diaz dated August 13, 2020+ | 10-Q(Exhibit10.3) | 11/9/2020 | 000-26642 | ||
| 10.12 | Performance-Based Non-Qualified Stock Option Agreement between the Registrant and Paul J. Diaz dated August 13, 2020+ | 10-Q(Exhibit10.4) | 11/9/2020 | 000-26642 | ||
| 10.13 | Non-Qualified Stock Option Agreement between the Registrant and Paul J. Diaz dated August 13, 2020+ | 10-Q(Exhibit10.5) | 11/9/2020 | 000-26642 | ||
| 10.14 | Form of Separation and Release Agreement between the Registrant and Paul J. Diaz+ | 10-Q(Exhibit10.6) | 11/9/2020 | 000-26642 | ||
| 10.15 | Executive Employment Agreement, dated October 17, 2023, between Myriad Genetics, Inc. and Samraat S. Raha+ | 10-Q (Exhibit 10.2) | 11/7/2023 | 000-26642 | ||
| 10.16 | Severance and Change of Control Agreement, dated December 11, 2023, by and between Myriad Genetics, Inc. and Samraat S. Raha+ | X | ||||
| 10.17 | Executive Employment Agreement, dated December 15, 2023, between Myriad Genetics, Inc. and Scott Leffler+ | X | ||||
| 10.18 | Separation and Consulting Agreement and Release of Claims, dated December 15, 2023, between Myriad Genetics, Inc. and R. Bryan Riggsbee+ | X | ||||
| ExhibitNumber | Exhibit Description | Filed with thisReport | Incorporated byReference hereinfrom Form orSchedule | Filing Date | SEC File/RegistrationNumber |
|---|---|---|---|---|---|
| 10.19 · Separation and Consulting Agreement and Release of Claims, dated October 4, 2023, by and between Myriad Genetics, Inc. and Nicole Lambert+ · X | |||||
| Equity Compensation Plans | |||||
| 10.20 | 2017 Employee, Director and Consultant Equity Incentive Plan, as amended (June 1, 2023)+ | 8-K(Exhibit 10.1+) | 6/2/2023 | 000-26642 | |
| 10.21 | Form of Restricted Stock Unit Agreement under the 2017 Equity Incentive Plan+ | 10-K(Exhibit 10.11) | 8/13/2020 | 000-26642 | |
| 10.22 | Amended and Restated 2012 Employee Stock Purchase Plan + | 8-K(Exhibit 10.1) | 6/2/2022 | 000-26642 | |
| 10.23 | Form of Restricted Stock Unit Agreement under the 2017 Equity Incentive Plan (Employee)+ | 10-Q (Exhibit 10.1) | 5/4/2023 | 000-26642 | |
| 10.24 | 2013 Executive Incentive Plan, as amended+ | 8-K(Exhibit 10.2) | 12/1/2017 | 000-26642 | |
| Credit Agreement | |||||
| 10.25 | Credit Agreement dated June 30, 2023, among Myriad Genetics, Inc., the other loan parties from time to time party thereto, the lenders from time to time party thereto, and JPMorgan Chase Bank, N.A., as the administrative agent and issuing bank. | 8-K (Exhibit 10.1) | 7/6/2023 | 000-26642 | |
| 10.26 | Pledge and Security Agreement dated June 30, 2023, among Myriad Genetics, Inc., each of the other Guarantors and JPMorgan Chase Bank, N.A., as administrative agent for the secured parties. | 8-K (Exhibit 10.2) | 7/6/2023 | 000-26642 | |
| 10.27 | First Amendment to Credit Agreement and Pledge and Security Agreement, dated as of October 31, 2023, among Myriad Genetics, Inc., the other loan parties party thereto, the lenders party thereto, and JPMorgan Chase Bank, N.A., as administrative agent. | 8-K (Exhibit 10.1) | 10/31/2023 | 000-26642 | |
| Other Exhibits | |||||
| 21.1 | List of Subsidiaries of the Registrant | X | |||
| 23.1 | Consent of Independent Registered Public Accounting Firm (Ernst & Young LLP) | X | |||
| 24.1 | Power of Attorney (included in the signature page hereto) | X | |||
| ExhibitNumber | Exhibit Description | Filed with thisReport | Incorporated byReference hereinfrom Form orSchedule | Filing Date | SEC File/RegistrationNumber |
| 31.1 | Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | X | |||
| 31.2 | Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | X | |||
| 32 | Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | X | |||
| 97.1 | Clawback Policy | X | |||
| 101 | The following materials from Myriad Genetics, Inc.’s Annual Report on Form 10-K for the year ended December 31, 2022, formatted in XBRL (eXtensible Business Reporting Language): (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Operations (iii) Consolidated Statements of Comprehensive Loss, (iv) Consolidated Statements of Stockholders’ Equity, (v) Consolidated Statements of Cash Flows, and (vi) Notes to Consolidated Financial Statements. Inline XBRL Instance Document – Instance Document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | X | |||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | X | |||
(+) Management contract or compensatory plan arrangement.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.